company background image
ESTA

Establishment Labs HoldingsNasdaqCM:ESTA Stock Report

Market Cap

US$1.5b

7D

-4.8%

1Y

114.4%

Updated

04 Dec, 2021

Data

Company Financials +
ESTA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ESTA Stock Overview

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.

Establishment Labs Holdings Competitors

Sientra

NasdaqGS:SIEN

US$221.4m

HansBiomed

KOSDAQ:A042520

₩121.1b

Price History & Performance

Summary of all time highs, changes and price drops for Establishment Labs Holdings
Historical stock prices
Current Share PriceUS$63.24
52 Week HighUS$88.66
52 Week LowUS$27.11
Beta1.1
1 Month Change-21.44%
3 Month Change-15.32%
1 Year Change114.37%
3 Year Change139.55%
5 Year Changen/a
Change since IPO155.52%

Recent News & Updates

Sep 25
Is Establishment Labs Holdings (NASDAQ:ESTA) Using Debt Sensibly?

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

ESTAUS Medical EquipmentUS Market
7D-4.8%-1.8%-2.7%
1Y114.4%8.9%16.6%

Return vs Industry: ESTA exceeded the US Medical Equipment industry which returned 8.9% over the past year.

Return vs Market: ESTA exceeded the US Market which returned 16.6% over the past year.

Price Volatility

Is ESTA's price volatile compared to industry and market?
ESTA volatility
ESTA Average Weekly Movement6.7%
Medical Equipment Industry Average Movement7.4%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: ESTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ESTA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004713Juan Jose Chacon Quiroshttps://www.establishmentlabs.com

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Establishment Labs Holdings Fundamentals Summary

How do Establishment Labs Holdings's earnings and revenue compare to its market cap?
ESTA fundamental statistics
Market CapUS$1.52b
Earnings (TTM)-US$32.60m
Revenue (TTM)US$118.33m

12.8x

P/S Ratio

-46.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ESTA income statement (TTM)
RevenueUS$118.33m
Cost of RevenueUS$42.51m
Gross ProfitUS$75.82m
ExpensesUS$108.42m
Earnings-US$32.60m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.36
Gross Margin64.08%
Net Profit Margin-27.55%
Debt/Equity Ratio83.4%

How did ESTA perform over the long term?

See historical performance and comparison

Valuation

Is Establishment Labs Holdings undervalued compared to its fair value and its price relative to the market?

24.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ESTA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ESTA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ESTA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: ESTA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ESTA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ESTA is overvalued based on its PB Ratio (24.7x) compared to the US Medical Equipment industry average (3.7x).


Future Growth

How is Establishment Labs Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

63.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ESTA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ESTA's is expected to become profitable in the next 3 years.

Revenue vs Market: ESTA's revenue (25.5% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ESTA's revenue (25.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ESTA is forecast to be unprofitable in 3 years.


Past Performance

How has Establishment Labs Holdings performed over the past 5 years?

-5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ESTA is currently unprofitable.

Growing Profit Margin: ESTA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ESTA is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare ESTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESTA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: ESTA has a negative Return on Equity (-52.95%), as it is currently unprofitable.


Financial Health

How is Establishment Labs Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ESTA's short term assets ($124.7M) exceed its short term liabilities ($30.5M).

Long Term Liabilities: ESTA's short term assets ($124.7M) exceed its long term liabilities ($56.3M).


Debt to Equity History and Analysis

Debt Level: ESTA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ESTA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESTA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ESTA has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 10.6% each year.


Dividend

What is Establishment Labs Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ESTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ESTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESTA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ESTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Juan Jose Chacon Quiros (49 yo)

8.92yrs

Tenure

US$598,158

Compensation

Mr. Juan Jose Chacon Quiros Founded Establishment Labs, S.A. in 2004 and has been its Chief Executive Officer. Mr. Chacon Quiros has been Chief Executive Officer and Executive Director of Establishment Lab...


CEO Compensation Analysis

Compensation vs Market: Juan Jose's total compensation ($USD598.16K) is below average for companies of similar size in the US market ($USD3.71M).

Compensation vs Earnings: Juan Jose's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ESTA's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: ESTA's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ESTA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Establishment Labs Holdings Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Establishment Labs Holdings Inc.
  • Ticker: ESTA
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.518b
  • Shares outstanding: 24.00m
  • Website: https://www.establishmentlabs.com

Number of Employees


Location

  • Establishment Labs Holdings Inc.
  • Building B15 and 25
  • Coyol Free Zone
  • Alajuela
  • Costa Rica

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:17
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.